Jonathan D. Tward, MD, PhD, FASTRO

University of Utah

Salt Lake City, Utah

Jonathan D. Tward, MD, PhD, FASTRO is a tenured Professor in the Department of Radiation Oncology at the University of Utah, where he also serves as the physician lead on several operational committees and working groups.. Dr. Tward holds the The Vincent P. and Janet Mancini Presidential Endowed Chair at Huntsman Cancer Institute (HCI) in Genitourinary Malignancies and is the leader of the HCI Genitourinary Cancers Center (GUCC). In that role, Dr. Tward is responsible for the strategic vision and operations of the GUCC, including the multidisciplinary collaboration of patient care, community engagement, research, and donor relations. Before joining HCI, Dr. Tward founded and served as the CEO or on the Board of Directors for several pioneering ecommerce and health-related websites. Dr. Tward earned a bachelor's degree in biology at the University of California, Los Angeles, a PhD in biochemistry, and an MD at Tufts University in Boston, Massachusetts. He completed a residency in radiation oncology at the University of Utah. 

Dr. Tward is an expert at delivering highly precise and targeted radiation therapy to people afflicted with cancers of the prostate, bladder, kidney, testis, and penis. He uses the vast array of technologies available at the HCI to deliver intensity-modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), stereotactic body radiotherapy (SBRT), as well as low-dose-rate (LDR) and high-dose-rate (HDR) brachytherapy.

As a practicing physician and scientist, mentor, and educator, Dr. Tward has contributed to over 80 published-peer reviewed journal articles. He is the Principal Investigator (PI) on several ongoing investigator-initiated clinical trials and is the site PI on numerous cooperative group or industry-sponsored clinical trials. Dr. Tward serves as the Utah State Captain for the American Society of Radiation Oncology (ASTRO) and on the National Comprehensive Cancer Networks (NCCN) clinical practice guidelines committees for prostate, bladder, and penile cancers. As a member of the NCCN Framework for Resource Stratification subcommittees, Dr. Tward helps define appropriate cancer treatment pathways of low- and middle-resource countries where specific diagnostic tests or treatment approaches may be unavailable.